Shield Therapeutics and Norgine enter into an exclusive license agreement for Feraccru® in Europe, Australia and New Zealand

Torreya advised Shield on the license of Feraccru® in Europe, Australia and New Zealand

London, United Kingdom and Amsterdam, Netherlands, September 19, 2018

Shield Therapeutics, a London based specialty pharmaceutical company, announced it entered into an exclusive licensing agreement with Norgine B.V. for the commercialization of Feraccru® in Europe, Australia and New Zealand. Feraccru® is Shield’s approved product for the treatment of iron deficiency in adults.

Under the terms of the agreement, Shield will receive an upfront payment of £11 million and up to €54.5 million in development and sales milestones. Shield will also receive tiered royalties ranging from 25% to 40% of net sales of Feraccru®. Shield retains full commercial rights to Feraccru® in all unlicensed countries including the US. Shield also retains full ownership of the global intellectual property rights to Feraccru® including the responsibility for completing an ongoing AEGIS-H2H study. The deal extends Shield’s cash runway to continue to develop Feraccru®, as well as pursue further opportunities to out-license.

Torreya served as financial advisor to Shield on this transaction. This transaction reinforces Torreya’s strength and leadership position as an advisor to life sciences companies. Torreya has advised on 15 completed strategic and financing transactions in the life sciences industry thus far in 2018.

ABOUT SHIELD THERAPEUTICS, PLC:
For more information about Shield, please see: www.shieldtherapeutics.com

ABOUT NORGINE B.V.:
For more information about Norgine, please see: www.norgine.com

Deal Press Release

Torreya Contact

STEPHANIE LÉOUZON
Partner | London Office
stephanie.leouzon@torreya.com | +44 (0) 207.451.4551 | torreya.com